Literature DB >> 2015725

Genetic aspects of variability in superficial vein responsiveness to norepinephrine.

A Luthra1, K R Borkowski, S G Carruthers.   

Abstract

Venoconstriction of the dorsal hand vein by local norepinephrine infusion was measured by the linear variable differential transformer method in 15 healthy unrelated subjects and eight pairs of monozygotic and six pairs of dizygotic twins. Incremental norepinephrine infusion produced dose-related venoconstriction. In unrelated subjects the doses of norepinephrine constricting basal vein diameter by 50% (ED50) ranged from 3.9 to 120.5 ng/min. There was a positive linear relationship between doses of norepinephrine infused and local steady-state plasma concentrations of norepinephrine achieved in each subject. The reciprocals of the slopes of these dose-concentration relationships, which reflect local norepinephrine clearance (disposition) in the vein, ranged from 0.47 to 1.86 ml/min. Plasma concentrations of norepinephrine associated with reduction of basal vein diameter by 50% (EC50) ranged from 1.4 to 110.2 ng/ml, with variability similar to that of ED50. There was a very high level of concordance in ED50, EC50, and clearance of norepinephrine within pairs of monozygotic twins but not within dizygotic twins. Differences in pharmacokinetics of infused norepinephrine exert a minor impact on overall intersubject variability. Genetic aspects of "tissue responsiveness" (i.e., vascular alpha-adrenoceptor response, smooth muscle contractility, and endothelial function) appear to be largely responsible for the wide intersubject variability in venoconstrictor responsiveness to norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015725     DOI: 10.1038/clpt.1991.41

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Clinical pharmacology, physiology and pathophysiology of superficial veins--2.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

2.  Effects of neuropeptide Y and vasoactive intestinal peptide on human venous smooth muscle in vivo.

Authors:  M Wolzt; W Gerschlager; B Zweytick; B Jilma; H Riemer; K Sertl; H G Eichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

3.  A polymorphism in the protein kinase C gene PRKCB is associated with α2-adrenoceptor-mediated vasoconstriction.

Authors:  Jussi P Posti; Perttu Salo; Saku Ruohonen; Laura Valve; Mordechai Muszkat; Gbenga G Sofowora; Daniel Kurnik; C Michael Stein; Markus Perola; Mika Scheinin; Amir Snapir
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

4.  Effects of serotonin and noradrenaline on superficial hand veins in patients with primary hypertension and in healthy volunteers.

Authors:  M Wolzt; E Schmidt; B Wagner; S Schuller-Petrovic; P A Kyrle; H G Eichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

5.  Asymptomatic peripheral nerve dysfunction and vascular reactivity in IDDM patients with and without microalbuminuria.

Authors:  C W Bodmer; E A Masson; M W Savage; S Benbow; A W Patrick; G Williams
Journal:  Diabetologia       Date:  1994-10       Impact factor: 10.122

6.  Genetic variation in the α1A-adrenergic receptor and phenylephrine-mediated venoconstriction.

Authors:  A Adefurin; L V Ghimire; U Kohli; M Muszkat; G G Sofowora; C Li; S Y Paranjape; C M Stein; D Kurnik
Journal:  Pharmacogenomics J       Date:  2014-11-25       Impact factor: 3.550

7.  Genetic variation in the alpha1B-adrenergic receptor and vascular response.

Authors:  A Adefurin; L V Ghimire; U Kohli; M Muszkat; G G Sofowora; C Li; R T Levinson; S Y Paranjape; C M Stein; D Kurnik
Journal:  Pharmacogenomics J       Date:  2016-04-19       Impact factor: 3.550

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.